Cibus pioneers vitamin D production increase technology

On May 5th, Cibus, a pioneer in agricultural precision gene editing, announced that its microbial strain development subsidiary, Nucelis, had received an item from the US Patent and Trademark Office for improving the production efficiency of vitamin D. New patents. Built on the comprehensive intellectual property portfolio of Nucelis and Cibus, the new patents are related to improving the production efficiency of vitamin D2 and D3, both of which are high-value ingredients in the food, functional food and pharmaceutical industries.


Nucelis President and CEO Sean O'Connor said: "By helping vitamin D2 and D3 manufacturers to significantly improve efficiency and reduce costs, new patents will further consolidate Nucelis' market position. New technologies developed with our proprietary gene editing technology With yeast strains, we are able to ferment key vitamin D intermediates. This increases Cibus ’intellectual property portfolio, which includes more than 350 patents, including intellectual property for precise natural gene editing of plants and microorganisms."


In addition, Laszlo Treiber, a researcher and sole inventor of patents of Nucelis, commented: "We are very excited to release and protect this new method. As we become more aware of the importance of vitamin D for human health, it is important to efficiently produce vitamin D continuously The medical community has also focused more on vitamin D in the past few years. Vitamin D deficiency will increase the incidence of fractures, cardiovascular disease, autoimmune and thyroid diseases, cognitive deterioration and certain cancers. "